KRAS in Stage IV Non-Small Cell Lung Cancer

Know about the book -

KRAS in Stage IV Non-Small Cell Lung Cancer is written by Georgia Hardavella and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832561519 (ISBN 10) and 9782832561515 (ISBN 13).

The oncogenic impacts of the KRAS gene were first reported in the 1980s, making KRAS one of the first identified oncogenes. A KRAS mutation occurs in nearly 30% of human cancers. Also in NSCLC KRAS mutations are often observed. In western populations, KRAS is the most common oncogenic driver mutation in NSCLC, occurring in 30% of patients. In patients with non-small cell lung cancer (NSCLC) that harbor a KRAS mutation, the KRAS G12C sub mutation is seen in 40-45%. Now that G12C inhibitors are available as a second line of therapy in metastatic NSCLC patients with a KRAS G12C mutation, we aim within this Research Topic to learn more about KRAS and its sub mutations and co-mutations in NSCLC.